Mylan Laboratories, Inc. (NASDAQ:MYL)

Steady as a rock.

Bearish head and shoulders pattern, too far too fast.

generic xanax

Mylan has seen and should continue to see rapidly expanding revenues due to the patent cliff and expanding prescription drug coverage. Add a robust share repurchase program and 11x forward earnings is a pittance to pay for a stock that has trounced the S&P over the past 5 years.

Nasdaq in maximums.

TP 31

Generic drugs like the industry. Positive insider transactions in last six months. Stats look not bad.

Mylan is a great value at the current share price of $22.82. Forward earnings support a share price of over $35. Look for Mylan to outperform on its way to a 35% gain over the next 12 months or so.

More generics means greater opportunity

Second largest generic company world wide. Baby boomers need drugs, generics cheaper and with medical cuts this industry will benefit the most.

With almost 80% of all medications by prescrition dispensed last year as a generic and with 14 major Branded Medications scheduled to loose patent protection in the next year or so these companies are positioned to grow substantially.I believe that we will see price controls or considerable pressure for lower brand name prescription prices from our government and the PBMs inorder to allow branded medications preferred status on formularies much like most other nations. We have recently seen the UK NICE folks turn down Novartis's fingolimod for MS at a deep discount to the US cost about $30,000 per patient per year in the UK vs. over $50,000 per patient per year in the US. We do not have the rersources to continue to cover these high cost medications especially when the data is largely less than life changing. Patients and health care providers need to wake up and demand patient oriented outcome data that matters to patients from the pharmaceutical industry before we jump on the new expensive brand name meduication band wagon and continue to spend ourselves into debt. Generic medications are at least one step in the "Right" direction especially when we have compitition from multiple manufacturers. and as long as they are FDA approved and rated as generically equivalent I have no problem taking or recommending them.

key03, no dividend

Mylan makes generic drugs and the name brand companies are not investing in new drugs. 5, 6 or 7 years down the road more patents will expire and those drugs will go generic. People will want cheaper drugs in this economy. Mylan is building a new warehouse that is already 60% of capacity before the first wall went up.

the signs are there...

Improved sales of generics with economic doubt in US now.

watch

Just got FDA approval to market generic versions of Flomax and Desoxin

people buy generics...

Here is all you want to know. Take a look at CEO open market stock purchase in 2008-2009
95000 shares between $10 - $13

Mr. Robert J. Coury , 49
Chairman and Chief Exec. Officer
25-Feb-09 10,000 MYL Purchase at $12.97 per share.
(Cost of $129,700)
24-Feb-09 15,000 MYL Purchase at $12.90 per share.
(Cost of $193,500)
23-Feb-09 25,000 MYL Purchase at $12.86 per share.
(Cost of $321,500)
27-Jul-08 30,591 MYL Option Exercise at $0 per share.
27-Jul-08 12,107 MYL Disposition (Non Open Market) at $13.26 per share.
(Value of $160,538)
31-Mar-08 8,512 MYL Disposition (Non Open Market) at $11.60 per share.
(Value of $98,739)
18-Mar-08 25,575 MYL Option Exercise at $0 per share.
18-Mar-08 10,131 MYL Disposition (Non Open Market) at $11.18 per share.
(Value of $113,264)
7-Mar-08 20,000 MYL Purchase at $10.14 per share.
(Cost of $202,800)
6-Mar-08 10,000 MYL Purchase at $10.74 per share.
(Cost of $107,400)
5-Mar-08 15,000 MYL Purchase at $10.91 per share.
(Cost of $163,650)